- Report
- May 2025
- 210 Pages
Global
From €2265EUR$2,500USD£1,952GBP
- Report
- July 2025
- 186 Pages
Global
From €3465EUR$3,825USD£2,987GBP
€4077EUR$4,500USD£3,514GBP
- Report
- February 2024
- 112 Pages
Global
From €4303EUR$4,750USD£3,709GBP
- Report
- February 2024
- 80 Pages
United States
From €4303EUR$4,750USD£3,709GBP
- Report
- July 2021
- 115 Pages
Global
From €4303EUR$4,750USD£3,709GBP
- Report
- January 2024
- 150 Pages
Global
From €4394EUR$4,850USD£3,787GBP
- Report
- August 2023
- 94 Pages
Global
From €3500EUR$4,139USD£3,122GBP
- Report
- March 2024
- 132 Pages
Global
From €861EUR$950USD£742GBP
- Book
- April 2016
- 576 Pages
The IUCD (intrauterine contraceptive device) market is a subset of the medical device industry. IUCDs are small, T-shaped devices that are inserted into the uterus to prevent pregnancy. They are a long-acting, reversible form of contraception that can be used for up to five years. IUCDs are a popular choice for women who want a reliable form of contraception without the need for daily or weekly maintenance.
The IUCD market is highly competitive, with a range of products available from different manufacturers. The market is dominated by a few large players, such as Bayer, Merck, and Teva Pharmaceuticals. Other companies in the market include CooperSurgical, Hologic, and Allergan. Show Less Read more
